MAR 31, 2017 2:29 PM PDT

New Multiple Sclerosis Drug Wins FDA Approval

WRITTEN BY: Xuan Pham

The FDA recently approved the first drug for the treatment of relapsing forms of multiple sclerosis (MS). The announcement marks a significant achievement, which is expected to help the 400,000 MS patients in the US.

Multiple sclerosis is described as a demyelinating disease whereby the body’s immune system mistakenly attacks the myelin sheath covers in the brain and spinal cord. This disrupts the electrical signal traveling from the brain to the body, and leads to physical and neurologic disabilities. The progressive form of MS causes patients to slowly deteriorate over time, while the relapsing form causes patients to go through bouts of symptoms and recovery. There is no cure for either form of MS.

“Multiple sclerosis can have a profound impact on a person’s life,” said Billy Dunn, the director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This therapy not only provides another treatment option for those with relapsing MS, but for the first time provides an approved therapy for those with primary progressive MS.”

The drug is known on the market as Ocrevus (ocrelizumab), and it works by weakening the immune system. In particular, IV infusions of Ocrevus prevent the B cells from attacking the protective myelin covers.

Tested in patients with both forms of MS (the progressive form and the relapsing remitting form), Ocrevus seems to stop the inflammation process in the brain. This results in less fatigue and muscle weakness. Vision seems to also be improved. Furthermore, scans show significantly less brain loss with the help of ocrelizumab.

"The drug is so much more effective at shutting down inflammation," said David Hafler, an MS expert from the Yale School of Medicine.

Side effects associated with Ocrevus include infusion-related reactions, such as skin irritation, flushing, shortness of breath, and nausea. In addition, upper respiratory tract infections were among the most common side effect seen with the drug in both forms of MS.

Patients eager to be treated with Ocrevus will have to wait just a few more weeks. Furthermore, they should also be aware that this drug comes with a hefty price tag of $65,000 per year. Though the cost is substantial, it is reportedly on par with approved drugs for the other forms of MS.

Additional sources: CNN

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 27, 2021
Cardiology
New miRNAs Might Help Diagnose Severe Dilated Cardiomyopathy
APR 27, 2021
New miRNAs Might Help Diagnose Severe Dilated Cardiomyopathy
The heart is one of the most reliable parts of the body. It pumps day and night, delivering fresh oxygen and nutrients t ...
MAY 06, 2021
Clinical & Molecular DX
Sweat Sensor Can Tell If a Storm's Coming
MAY 06, 2021
Sweat Sensor Can Tell If a Storm's Coming
A surge of pro-inflammatory cytokines, intense, and sustained inflammation leading to organ damage and a high risk of de ...
JUN 01, 2021
Genetics & Genomics
Sequencing and Identifying SARS-CoV-2 Variants Efficiently
JUN 01, 2021
Sequencing and Identifying SARS-CoV-2 Variants Efficiently
  Viral surveillance can give researchers vital information about virus origins, transmission routes, affected popu ...
JUL 19, 2021
Cardiology
Immune Proteins & Blood Clots May be Connected to Psychosis Development
JUL 19, 2021
Immune Proteins & Blood Clots May be Connected to Psychosis Development
Researchers are pointing out the associations between blood clotting disruptions and the front line immune system, and t ...
AUG 17, 2021
Clinical & Molecular DX
Sleep Apnea Doubles the Risk of Sudden Death
AUG 17, 2021
Sleep Apnea Doubles the Risk of Sudden Death
Obstructive sleep apnea, or OSA, is the most commonly reported sleep disorder, with loud snoring being one of the tell-t ...
SEP 09, 2021
Clinical & Molecular DX
A Drug Test for Synthetic Cannabis Use
SEP 09, 2021
A Drug Test for Synthetic Cannabis Use
Designer drugs are synthetic analogs of prohibited substances such as cocaine and LSD made in clandestine laboratories a ...
Loading Comments...